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Abstract
Alzheimer's disease (AD) is characterized by plaques of amyloid–beta (Aβ) peptide, cleaved from 
amyloid–β precursor protein (AβPP). Our hypothesis is that lifespan profiles of AD-associated 
mRNA and protein levels in monkeys would differ from mice, and that differential lifespan 
expression profiles would be useful to understand human AD pathogenesis. We compared profiles 
of AβPP mRNA, AβPP protein, and Aβ levels in rodents and primates. We also tracked a 
transcriptional regulator of the AβPP gene, specificity protein 1 (SP1), and the β amyloid precursor 
cleaving enzyme (BACE1). In mice, AβPP and Sp1 mRNA and their protein products were 
elevated late in life; Aβ levels declined in old age. In monkeys, Sp1, AβPP, and BACE1 mRNA 
declined in old age, while protein products and Aβ levels rose. Proteolytic processing in both 
species did not match production of Aβ. In primates, AβPP and Sp1 mRNA levels coordinate, but 
an inverse relationship exists with corresponding protein products, as well as Aβ levels. 
Comparison of human DNA and mRNA sequences to monkey and mouse counterparts revealed 
structural features that may explain differences in transcriptional and translational processing. 
These findings are important for selecting appropriate models for AD and other age–related 
diseases.
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Introduction
Alzheimer's disease (AD) is a progressive, irreversible neurodegenerative disorder resulting 
in memory loss, dementia, and death. It is characterized by senile plaques composed of 
aggregated amyloid–beta (Aβ), neurofibrillary tangles, and synaptic loss in the brain [1-6]. 
Autosomally inherited AD can be caused by mutations in the amyloid–β precursor protein 
(AβPP) and presenilin 1 (PSEN1) genes. However, this accounts for no more than 10% of 
cases [6]. In over 90% of cases, patients have “sporadic” AD not characterized by autosomal 
inheritance. The APOE ε4 allele [7, 8] the only confirmed genetic risk factor for sporadic 
AD, accounts for a minority of the disorder [9], and the etiology of most sporadic AD cases 
remains unknown.
The accumulation of amyloidogenic Aβ peptides from cleavage of AβPP has been studied 
extensively. Human AβPP and/or PS–1 transgenic rodent animal models [10-14] are widely 
used to study molecular and biological processes underlying AD pathogenesis. While these 
animal models demonstrate AD–like pathologies and behavioral changes compared to wild–
type animals, they carry mutant forms of AD–related genes, driven by promoters other than 
those of the respective genes. Thus, AβPP is over-expressed and processed to speed up AD 
pathogenesis in a manner that may not be clinically relevant. Transgenic human AβPP in 
these rodents is cleaved by intrinsic β–secretase (BACE1) to produce Aβ. The preferred 
cleavage site by rodent BACE1 in human AβPP is different from that by which human 
BACE1 cleaves AβPP.
Although rodents and primates share more than 95% amino acid sequence homology in their 
respective AβPP proteins [15], the amyloid products from the two differ. Murid rodents do 
not aggregate Aβ peptides and, therefore, are non plaque–forming, but primates are human–
like in their ability for Aβ aggregation to form senile plaques. The Aβ peptide sequence from 
primates and murid rodents differ in three amino acids at residues 5 (R→G), 10 (Y→F) and 
13 (H→R). However, the primary sequence difference may not explain plaque–forming or 
non plaque–forming nature of the peptides, since in vitro experiments [16, 17] indicate that 
either peptide could aggregate. A difference has been noted in the 5′–untranslated region of 
the mRNA of non–plaque–forming vs. plaque–forming mammalian species, specifically, the 
absence of a “CAGA” box in non–plaque–forming species mRNA [18]. However, 
differences in processing of AβPP or Aβ metabolism in vivo may, likewise, determine 
amyloidogenesis. This is especially true if physiologic manifestations of aging are 
considered, and this paper seeks to address this issue.
The 5′-flanking regulatory region of the AβPP gene is rich in GC box elements and contains 
consensus sites that are recognized by several transcription factors, including specificity 
protein 1 (SP1) [19, 20]. SP1 binds to both the human and rat AβPP promoters and 
accelerates the production of AβPP mRNA [21-23], which can be further spliced to generate 
several cell-specific species. SP1 belongs to a family of zinc finger protein (ZFP) 
transcription factors that includes other members such as Sp2, Sp3, and Sp4 [24, 25]. Sp1 is 
a transcription factor involved in the pathology of AD [26, 27]. Furthermore, SP1 regulates 
the expression of BACE1 [28], the main form of β-secretase that cleaves AβPP to generate 
Aβ [29]. Likewise, silencing Sp1 gene dramatically reduces AβPP promoter activity [26]. In 
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addition, SP1 regulates the expression of the microtubule associated protein tau (MAPT) 
gene [30]. The buildup of hyper-phosphorylated tau protein results in the formation of the 
pathogenic tangles found in AD and some other neurodegenerative disorders like Pick's 
disease [27].
AD incidence increases exponentially after 65 years of age, making age the greatest risk 
factor for AD [31]. It is well known that the most common animal model species for AD 
(mouse) does not develop any similar conditions, requiring the use of transgenics or drug–
induced defects. Monkeys, on the other hand, have shown the spontaneous presence of β–
amyloid plaque [32]. and many genes known to be involved in human neurological disorders 
have been shown to be present and regulated in cynomolgus monkeys [33]. Likewise, 
administration of a modified version of the Cambridge Automated Neuropsychological Test 
Battery has determined that aged monkeys reveal patterns of age-related cognitive 
impairment that mirror in quality and severity those of aged humans [34].
We hypothesize that profiles of gene expression and protein levels of the AD–critical SP1, 
AβPP, and BACE1 genes, in mice would differ over the lifespan in a non–trivial fashion 
from those of a species closer to human, specifically cynomolgus monkey. These differences 
would be qualitative and appear at transcriptional, translational, and protein processing 
levels of gene expression. Therefore, we examined the pathways of AβPP production, 
processing, and accumulation of its Aβ cleavage product as a function of age. We compared 
differences in AD–related gene expression between rodents and primates. Our results 
suggest fundamental differences between rodents and primates in expression and processing 
of important AD–related genes and proteins. These differences occur at transcriptional, 
translational, and post–translation levels, potentially affecting applicability of animal model 
studies at several stages of understanding AD.
Materials and Methods
Animals and tissues
The C57Bl/6 mice were bred in house at University of Rhode Island. Male pups from 
different dams were pulled and selected randomly at the time of sacrifice. Brains were 
dissected at different ages, specifically three mice at each post–natal day (PND) 5, 20, 365, 
and 630, and brain frontal cortex tissues were stored at −80°C until use. The Cynomolgus 
monkey brain cortex tissues were obtained from National Institutes of Health (NIH), and 
were control monkeys from two separate studies [35]. They were kept at the NIH facility 
until termination at 3–6, 12, and 23 years of age, three animals at each of three timepoints. 
All animal procedures were conducted under the supervision of a licensed veterinarian 
according to a National Institute on Environmental Health Sciences–NIH–approved animal 
protocol. The tissues were kept frozen until use in our study.
Total RNA isolation, synthesis of cDNA, and Real Time PCR
RNA from the brain tissue was isolated according to the TRIzol method (Invitrogen, 
Carlsbad, CA). The RNA was reverse transcribed to obtain cDNAs, catalyzed by 
SuperScript III (Invitrogen) reverse transcriptase (RT). The RNA/primer mixture containing 
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500 ng of total RNA, 1μl of 10mM dNTP mixture, and 1μl Oligo(dT) were incubated at 
65°C for 5 min. A reaction mixture containing 2 μl of 10× RT buffer [200 mM Tris–HCl 
(pH 8.4), 500 mM KCl], 4 μl of 25 mM MgCl2, 2 μl of 0.1 M DTT and 1 μl of RNaseOUT 
(Invitrogen) recombinant RNase inhibitor (40 U/μl) was added. One microliter of 
SuperScript III RT (200 U/μl) was then added and incubated at 50°C for 50 min. The 
reaction was terminated at 85°C for 5 min. One microliter of RNase H was added and the 
reaction was incubated for 20 min at 37°C. The resulting cDNA was stored at −20°C and 
used in the real time PCR step. The primer pairs used for mouse AβPP, SP1, and β–actin are 
described in Table 1. Each real time PCR reaction mix contained 1 μl of cDNA, 1 μl of 
primer mix (final concentration 200 nM), 10.5 μl of nuclease free water and 12.5 μl SYBR® 
GREEN PCR Master Mix (Applied Biosystems, CA). Each sample was done in triplicate. 
Real Time PCR was conducted for all above genes with respective primer pairs in a 7500 
Real–Time PCR System following standard protocol. The initial step was 50 °C for 2 min 
followed by 95 °C for 10 min, then 40 cycles of 95 °C for 15 sec and 60 °C for 1min. Real 
time PCR products were checked with agarose gel to confirm no non–specific products 
formed. Results were analyzed with 7500 system software with relative quantification 
method using β–actin or GAPDH as endogenous controls.
Western Blot
Brain tissues were homogenized in RIPA buffer containing protease inhibitor cocktail 
(Promega), incubated on ice for one hour then centrifuged at 3500 × g for 20 min [26]. The 
supernatant was collected and used for western blot. Protein concentration was determined 
by BCA kit (Pierce Biotechnology, Inc. Rockford, IL). A 10 μg of total protein from each 
sample was applied for western blot. Protein samples were denatured and resolved in 8% 
SDS–PAGE then transferred to PVDF membrane. The membrane was blocked with 5% 
non–fat milk in Tris buffered saline (TBS, pH 7.4) for one hour, then 22C11 AβPP N–
terminal specific antibody (1:1000) was incubated with 5% milk in TBS overnight at 4°C. 
For SP1, the membrane was incubated with SP1 (H-225) polyclonal antibody (1:200). The 
membrane was washed with TBST (TBS + 0.5% Tween–20) 4 times before adding 
horseradish peroxidase conjugated goat anti–rabbit IgG (1:1000, Pierce). Each membrane 
was incubated at room temperature for 60 min followed by sequential wash with TBST 4 
times and TBS 4 times then developed by Amersham ECL Plus Western Blotting Detection 
System and exposed with Typhoon 9410 MultiMode Scanner. Signals were normalized to 
GAPDH or Actin signal of same lanes.
Beta amyloid (Aβ) 1–40 assay
The levels of Aβ were measured with human Aβ 1–40 assay kits (Immuno–Biological 
Laboratories, Gunma Japan). These kits were designed as solid phase sandwich ELISA with 
highly specific antibody. The assay conditions were followed according to the method 
described previously, [36] with slight modifications. Brain tissue was homogenized in Tris–
Saline (TS) [50 mM Tris–HCl buffer, pH 7.4; 150 mM NaCl; 1 μg/mL TLCK (N–Alpha–p–
tosyl–L–Lysine chloromethyl ketone); 1 μg/mL antipain; 0.5 mM DIFP (Diisopropyl 
fluorophosphates); 1 mM PMSF; 1 mM NaF; 0.25% sodium deoxycholate; 0.5% SDS; 0.1% 
Protease Inhibitor cocktail], incubated on ice for one hour, then centrifuged at 3500 g for 20 
min at 4°C. The resultant supernatant was collected and diluted by EIA buffer (supplied with 
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the kit) to 1 μg/μl (100 μg of protein in 100 μl EIA buffer) and assay standards were added to 
a 96 well plate (pre–coated with anti–human Aβ (35–40) (1A10) Mouse IgG monoclonal 
antibody) and incubated overnight at 4°C. The wells were washed 7 times with EIA buffer. 
Then 100 μl of labeled antibody was added to each well containing sample or standard and 
incubated at 4°C for 1 hour. The wells were washed 9 times with EIA buffer followed by the 
addition of 100 μl of TMB buffer and incubated in the dark for 30 min at room temperature. 
The reaction was stopped by adding 100 μl of 1N H2SO4 and the colorimetric absorption 
was taken at 450 nm. The levels of Aβ in the test samples were calculated relative to the 
standard curve generated on each plate.
BACE1 activity assay
β–secretase activity was conducted with BACE1 activity kit (R&D Systems, Inc. 
Minneapolis, MN) following manufacturer's protocol with small modifications. The 
enzymatic reaction for secretase activity was carried out in the black uncoated microplate 
provided, with controls provided in the kit. Total protein from brain tissue homogenate was 
diluted to 1 μg/μl with 1X Cell Extraction Buffer. Then 50 μl of protein sample was added to 
each well. Each sample was run in duplicates for greater accuracy. Next, to each well, 50 μl 
of 2X Reaction Buffer was added to each well plus 5 μl of substrate at room temperature to 
each well. Negative controls run were a) no protein sample and b) no substrate. The plate 
was covered by provided film, tapped gently to mix, and incubated at 37° C for 2 hours in 
the dark. The plate was read on a fluorescent microplate reader using light filters that allow 
for wavelength excitation between 335–355 nm and emitted light between 495–510 nm was 
recorded.
Statistical analysis
Results from mRNA expression, protein or peptide level, and enzymatic activity assays were 
subject to t–test against “adult” data points, “adult” defined as PND 365 for mice and 12 
years age for monkeys. Average values with p < 0.05 vs. their respective “adult” data points 
were deemed significant.
DNA sequence homology analysis of mouse and monkey Sp1 and AβPP genes vs. human 
Sp1 and AβPP genes
The NCBI human genome database (build 36.2) was consulted for the reference sequences 
of the human Sp1 and AβPP genomic sequences. A portion of reference sequence 
NC_000012 from 52056246 to 52096497 was selected for Sp1 BLAST, and the AβPP 
reference sequences NG_007376.1 was used for BLAST. Cynomolgus monkey (Macaca 
fascicularis) genomic sequences were not available; therefore, rhesus monkey (Macaca 
mulatta) sequences were used. BLAST comparison of the available cynomolgus sequence 
vs. rhesus sequences showed 99% or greater homology (data not shown) between the two. 
Each sequence was used to probe the rhesus monkey (build 1.1) and mouse (build 37.1) 
NCBI reference genome databases. In addition, sequences of 4kb upstream of the +1 
transcription start site (TSS) of the Sp1 genes of mouse, rhesus monkey, and human were 
extracted from their respective NCBI genomic databases, and the monkey and mouse Sp1 
sequences were each compared with the human Sp1 sequence via ClustalX [37].
Dosunmu et al. Page 5
J Alzheimers Dis. Author manuscript; available in PMC 2016 February 22.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Transcription factor binding site analysis of promoters of Sp1 for human, mouse, and 
monkey
Sequences 4kb upstream of the +1 TSS of the Sp1 genes of mouse, rhesus monkey, and 
human were used to search for putative transcription factor binding sites via the 
MatInspector utility of the Genomatix analysis package [38]. Results for each species were 
compared, and predicted factor binding sites unique to mouse or shared by monkey and 
human but absent in mouse were recorded.
Motif analysis of 5′– and 3′–untranslated regions (UTRs) of AβPP for human, mouse, and 
monkey
The RegRNA database/analysis utility [39] was employed to search the sequences of the 
human (GenBank Accession #NM_000484), cynomolgus monkey (M58727), and mouse 
(NM_007471) AβPP mRNA 5′– and 3′–UTRs. For consistency with our previous 
publications, the +1 transcription start site (TSS) producing a 147bp 5′–UTR [19] was 
selected for the human AβPP sequence rather than a further–upstream TSS that produces a 
194bp 5′–UTR. UTR sequences were searched for conventional regulatory motifs and 
miRNA homology sites.
Results
Our purpose in comparing AD–associated gene expression between monkeys and mice is to 
establish comparative non–pathological “baselines” for disease–critical genes and their 
protein products. We hypothesized that non–trivial, qualitative differences exist between 
primate and rodent expression in fundamental AD–associated genes at transcriptional, post–
transcriptional, and protein processing levels. Profiling of AD–associated gene expression 
and protein levels in the lifespan of monkeys and mice produces control profiles of animal 
models, which develop an understanding of “baseline” normal aging effects on 
transcriptional, translational, and post–translational mechanisms. These baselines then form 
a basis for evaluating overall model performance in comparison to human aging and 
pathological processes. The data reported below are the results of measuring AβPP, BACE1 
and Sp1 gene expression as well as their protein levels in the brain frontal cortices of wild–
type mice and primates. In addition, comparative results of pertinent DNA and mRNA 
sequences and sub–sequences of the AβPP, BACE1, and Sp1 genes are presented.
AβPP, BACE1, and Sp1 mRNA expression in mice at different ages
The mRNA expression of AβPP and Sp1 was examined by real time PCR at 6 different 
times within the mouse life span and normalized to β–actin PCR signal, PND 5 through 630. 
In mice, normalized AβPP mRNA signal increased dramatically from PND 5 to PND 20, 
remained steady throughout adulthood, and increased again upon aging (Fig. 1A). 
normalized Sp1 mRNA expression showed the same trend as that of the AβPP mRNA (Fig. 
1B); however, normalized BACE1 mRNA did not show any trend with aging (data not 
shown).
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AβPP, SP1, and Aβ1–40 levels in mice at different ages
SP1 and AβPP protein levels were determined by Western blot analysis and normalized to 
β–actin, and Aβ levels were measured using an ELISA assay (Fig. 2A, 2B, and 2C). 
Normalized AβPP levels slightly increased during development, remained steady during 
adulthood, and sharply rose in old age (Fig. 2A). Normalized SP1 levels on the other hand 
did not change on PND 20 but showed a similar increase in old age (Fig. 2B). Aβ levels on 
the other hand dropped on PND 20, rose to adult levels by PND 365, but exhibited a sharp 
decline in old age at PND 630 (Fig. 2C). The profile of the SP1 and AβPP proteins was 
similar to the pattern of AβPP and Sp1 mRNA expression in old age (Fig. 1 vs. 2).
AβPP, BACE1, and Sp1 mRNA expression in monkeys at different ages
In the three monkey age groups, both GAPDH–normalized AβPP and normalized BACE1 
mRNA were independently elevated in the adult group (12–year old), but decreased in the 
aged 23–year old group (Fig. 3A and 3B). As was the case in mice, normalized Sp1 mRNA 
expression showed the same trend as normalized mRNA of AβPP (Fig. 1 vs. 2). Unlike in 
mice, BACE1 mRNA decreased in monkey.
AβPP, SP1 protein expression and Aβ1–40 levels in monkeys at different ages
The total β–actin–normalized AβPP protein level in monkeys increased linearly as they aged 
(Fig. 4A). The plaque–forming primates accumulated AβPP protein in their brain as they 
aged despite their inverse relationship to the AβPP mRNA (Fig. 3 vs. 4). Normalized SP1 
levels on the other hand, remained steady during adulthood but sharply rose in old age (Fig. 
4B). In monkeys, there was an age–dependent increase in Aβ1–40 levels (Fig. 4C), which 
was consistent with normalized AβPP protein levels.
BACE1 activity in mice and monkeys at different ages
BACE1 is the proteolytic enzyme that generates the N–terminus of Aβ peptide. Our study 
showed that BACE1 activity remained relatively steady in young and aging mice (Fig. 5A). 
In monkeys, BACE1 activity appears to decrease in old age (Fig. 5B), although this decrease 
is not significant at p < 0.05. In both mice and monkeys, BACE1 activity does not appear to 
follow the same pattern as AβPP or Aβ levels.
Genomic sequence homologies of monkey and mouse Sp1 and AβPP sequences with 
human sequence
Structural similarities and differences in genomic sequences are often reflected in 
differences in transcription and hnRNA processing. We examined the respective Sp1 genes 
of monkey (40kb) and mouse (39kb) vs. human (40kb) genomic sequences via BLAST. 
When the mouse genomic sequence database was BLAST probed with the human genomic 
sequence for Sp1 (Fig. 6A), coverage of homologous regions attained 19% of total human 
genomic sequence with an identity of 91% over the longest homologous sub–sequence. 
Coverage of homologous regions between human (300kb) AβPP and mouse (290kb) AβPP 
sequences (Fig. 6B) was 3%, with an identity of 85% over the longest homologous sub–
sequence. Comparison of monkey and human Sp1 genomic sequences (Fig. 6C) revealed 
63% coverage with a 95% homology for the longest homologous sub–sequence. Coverage 
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of homologous regions between human and monkey (300kb) AβPP sequences (Fig. 6D) was 
91% with an identity of 91% over the longest homologous sequence. These differences 
between mouse and monkey in structural homology to the human AD–related genes Sp1 and 
AβPP are not unexpected and indicate that fundamental gene regulatory variation should, 
likewise, be expected between rodent model systems and human AD.
Sp1 promoter sequence homologies vs. human
Promoter homology comparison in a 50bp window (up to 4kb upstream of the +1 TSS) of 
Sp1 (Fig. 7A) produced two distinct running profiles when comparing mouse vs. human and 
monkey vs. human. Homology between mouse and human sequences was mostly between 
25% and 50% from −4000 to −1600 on the human sequence, counting the TSS as +1, when 
it rose to around 75% from −1400 to −100 (human sequence numbering). From −100 
through the 5′–UTR (+1 to +101), homology was between 90% and 100%. When comparing 
monkey to human Sp1 5′–flanking sequences (Fig. 7B), there was no region of homology 
between −4000 and −3709 on the human sequence. From −3709 to −2450, homology was 
85%–100%. A sharp drop in homology occurred at −2450 to −1950, where homology 
dropped to 25%, rose to 75% and then dropped back to 25%. From –1950 to the end of the 
5′–UTR (+101), homology of between 85% and 100% resumed.
Unique transcription factor binding sites predicted in Sp1 promoter of mouse vs. primate 
(monkey and human)
We used the human, monkey, and mouse Sp1 promoter sequences, 4kb upstream of the 
+1TSS, to probe the transcription factor database included in MatInspector (v. 7.7). 
Hundreds of sites were shared between both rodents and primates (data not shown). 
However, when the output was screened to include only those sites that were unique by 
transcription factor and transcription factor family, 18 different transcription factor families, 
each represented by a single factor, remained (Table 2). For mouse, the families were 
represented by transcription factors activator protein 2 (AP2), autoimmune regulatory 
element binding factor (AIRE), a barbiturate–inducible element (BARBIE), downstream 
immunoglobulin control element, critical for B cell activity and specificity (DICE), GTF2I-
like repeat 4 of GTF3 (GTF3R4), and Nuclear DEAF-1-related protein (NUDR).
Transcription factor families unique to the primate (human and monkey) sequences were 
represented by the specific factors of amino acid response element (AARE), T–box 
transcription factor 5 (TBX5), kaiso (a zinc–finger transcription factor), the factor for Friend 
leukemia integration site 1 (FLI), hypoxia inducible factor 1 (HIF1), hypermethylated in 
cancer 1 (HIC1), transcription factor 11 (TCF11), myocyte expression factor 3 (MEF3), 
Neuron–restrictive silencer factor (NSRF), Pancreas transcription factor 1 (PTF1), the 
Notch–associated factor RBPJκ (RBPJκ), and THAP domain containing, apoptosis 
associated protein 1 (THAP1).
Regulatory factor and miRNA binding sites in the 5′—UTR of human, monkey, and mouse 
AβPP
To assess potential pathways whereby differences in posttranscriptional regulation of 
primate vs. murid rodent AβPP may operate, the 5′– and 3′– UTRs of the human, 
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cynomolgus monkey, and mouse AβPP gene were analyzed via the RegRNA utility. In 
addition, some microRNA (miRNA) sites determined were redundant homologies, since 
both the human and mouse miRNA databases were used to search these sequences. In the 
5′–UTRs (Table 3), we noticed that all three species had terminal oligopyrimidine tracts 
(TOP), although the mouse sequence had only one while the human and monkey sequences 
had three. Furthermore, three different human miRNA homology sites (hsa–miR–346, 502, 
504) were found in both monkey and human sequences but not in the mouse (along with 
three sites for the homologous mouse miRNAs). One mouse miRNA homology site (mmu–
miR–328) was found in the mouse sequence (homologous to a single human miRNA) but 
neither in monkey nor human.
Regulatory sites in 3′–UTR in different species
Examining the 3′–UTR sequences of human, cynomolgus monkey, and mouse also revealed 
potentially important differences in regulatory motifs (Table 4). All three sequences had the 
AβPP mRNA stability control element (AβPP SCE). However, the mouse sequence alone 
possessed (two copies of) the cytoplasmic polyadenylation element (CPE). While all 
sequences had at least two copies of the gamma interferon activated inhibitor of 
ceruloplasmin mRNA translation (GAIT) motif, the human and monkey sequences had five 
more or four more such sites, respectively, than did the mouse. Similarly, human and 
monkey sequences had more selenocysteine insertion sequence (SECIS) motifs than did the 
mouse. The major difference noticed in regard to miRNA homology sites was that human 
and monkey sequences shared five (hsa–miR–17–5p, 20b, 106b, 483, 485–5p) human sites 
(with five homologous mouse miRNAs) found in mouse, while the mouse sequence had one 
unique mouse miRNA (mmu–miR–99b) site (with a homologous human miRNA).
Discussion
We undertook our study specifically to test a critical unspoken assumption in the field of AD 
research, that conventional rodent animal models can be presumed to be sufficiently similar 
to humans that results from the animal models can be “linearly applied” to the human 
condition. We, therefore, compared levels of proteins shown to be critical for AD etiology 
between murine rodents and primates, specifically to see how much actual similarity existed 
for the expression of these proteins between rodent models and primates (which would 
include humans).
Animal disease models are not necessarily “non–reactive vessels”—the substrate species has 
its own normal expression patterns and pathways for etiologically interesting genes. These 
patterns and pathways may or may not significantly resemble those of the ultimate target 
species, which for AD would be humans. It is not known whether or not “normal” 
expression patterns do or do not interact with AD models imposed on mice. An 
indispensible step in learning whether or not the mouse functions more as a “vessel” or as an 
“environment” for AD models is to understand lifetime non–diseased expression patterns of 
AD–associated genes. This understanding is enlarged in the context of translation of animal 
results to human subjects by comparing these patterns between mice and primates that are, 
presumably, more closely related to humans.
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The single most important risk factor in the etiology of Alzheimer's disease is age. The 
majority of research within the field “short–circuits” this risk factor by utilizing transfected 
cell cultures and short–lived natural or transgenic models. These “time–compressed” models 
of AD have not been evaluated by comparison to actual aging, particularly not for 
comparison of non–pathological lifespan expression of genes and proteins associated with 
AD, such as AβPP, BACE1, and Aβ between plaque forming (primate) and non–plaque 
forming (rodent) species.
In this study, constitutive AβPP and Sp1 mRNA expression mirror each other across the 
rodent lifespan and thus either gene could be biomarker for the other. These findings are 
consistent with previous siRNA studies, which showed a dramatic drop in AβPP promoter 
activity, if SP1 levels are depleted [26] and with other surveys of AβPP and Sp1 mRNA 
[40-42]. Immunohistochemical studies have shown that AβPP and SP1 co–localize to 
neurons and have a similar distribution in the brain [43]. These lifetime signatures establish 
SP1 as a partner transcription factor that controls AβPP expression across the lifespan.
BACE1 mouse mRNA levels remained unchanged (data not shown). This may indicate that, 
in mice, SP1 does not drive BACE1 mRNA expression in the same manner as does AβPP. 
Other studies have shown that, even when AβPP is transgenically up–regulated, BACE1 
mRNA levels do not alter significantly at different ages [44]. BACE1 over-expression with 
elevated mRNA level was only seen in genomic BACE1 transgenic mice [45].
In primates, the mRNA expression of AβPP, BACE1, and Sp1 showed the same trend 
among all age groups. Higher levels of Sp1 mRNA expression were accompanied by greater 
AβPP and BACE1 mRNA expression, and vice–versa. This would not be inconsistent with 
SP1 coordinately regulating both AβPP and BACE1 gene expression in primates. However, 
there was no elevation of mRNA expression for the genes in old age, instead, mRNA levels 
for those genes decreased in the oldest age group of mice.
Several studies have reported age related brain AβPP mRNA changes in cynomolgus 
monkeys, normal humans, and AD patients. A primate study [46] showed unchanged mRNA 
levels of AβPP751 and AβPP695 in cortical regions in the aged group in comparison to the 
young group, but expression in thalamus was significantly increased with a decreased 
AβPP695/AβPP751 ratio in aged monkeys. Another report found no differential expression 
of alternatively spliced AβPP mRNA transcripts in AD cases or aged monkeys [47]. A study 
reported that the mRNA ratio AβPP770+751/AβPP695 increased with age in AD patients 
[48], while another study found expression of major AβPP mRNA in neocortex declined as a 
function of age in both AD and control cases [49]. On the other hand, there was a report of 
no alteration of total AβPP mRNA as well as AβPP with Kunitz protease inhibitor (KPI) in a 
wide range of age group of control human subjects [50]. These contradictory results are 
probably caused by the methods for studying mRNA used by different studies. For example, 
solution hybridization–RNase protection assay [48, 50] is more sensitive and quantitative 
than the Northern blot analysis utilized by another group [49]. Moreover, several factors, 
such as gender, postmortem interval, and brain pH would affect the quantification of mRNA 
when postmortem brain tissues are utilized [51].
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In mice, AβPP and Sp1 gene expression and their protein products were elevated late in life; 
however Aβ levels declined in old age. In monkeys, Sp1, BACE1, and AβPP mRNA 
expression declined in old age, while their protein products, as well as Aβ levels, rose. In 
rodents, Aβ levels in old age do not appear to be maintained by the transcriptional or 
translational status of the AβPP gene but instead by enhanced degradation and clearance. In 
primates, there is an inverse relationship between AβPP and Sp1 mRNA levels and their 
corresponding protein products, as well as Aβ levels. While the specific mechanism of this 
disparity is not apparent, it suggests that enhanced translational efficiency or reduced protein 
degradation may account for a rise in AβPP consequently elevating Aβ levels in primates.
We found that BACE1 activity remains practically unchanged across the entire adult 
lifespan of mice and has a non–significant decrease in monkeys. Thus, BACE1 activity does 
not appear to mirror Aβ levels nor is it influenced by AβPP levels. Neither does it appear to 
match the decline in BACE1 mRNA levels in monkeys. We must note that currently 
available β–secretase activity assays are not necessarily specific for BACE1 if used on tissue 
extracts instead of purified BACE1 protein. However, of the alternatives, BACE1 is the 
primary β–secretase [29] and is likely to be responsible for most of the measured activity 
and changes in this activity.
We did note apparently dramatic changes between postnatal days 5 to 20 in levels of mouse 
SP1 and APP mRNA, in mouse APP and in mouse Aβ. While these results may help 
illuminate regulation of these genes in mouse, we have previously published in greater detail 
on developmental expression of such genes in rodents [26, 52, 53].
Given the differences we found in AβPP mRNA and protein levels between mouse and 
monkey, we examined homology at the genomic level. Rhesus monkey and human AβPP 
promoter sequences up to 4kb have previously been shown to have high (>90%) homology. 
[54]. The full–length (∼300kb) monkey genomic sequence preserved approximately 90% 
homology with the human reference AβPP genomic sequence, while mouse had no more 
than 3% homological regions. Respective Sp1 genomic sequences' homology comparison 
with human showed that monkey sequence had up to 63% homology coverage vs. 19% for 
mouse vs. human. The majority of non–homologous regions were intronic. Intronic 
regulation of mRNA levels has been well demonstrated [55, 56]. The large differences 
between mouse and monkey respective genomic Sp1 homologies to human likely contribute 
to differences in mRNA levels for this transcription factor, although greater differences in 
AβPP homologies do not seem to alter tight transcriptional control of AβPP by Sp1.
We also examined the promoters of monkey and mouse Sp1 genes for structural differences 
vs. the human Sp1 gene and determined very high homology (>90%) between monkey and 
human over most of 4kb upstream of the +1 TSS, while mouse and human homology 
remained around 75% for most of this length. In addition, the primate Sp1 promoter 
sequences were predicted to have several transcription factor binding sites absent in the 
mouse sequence. Of particular interest is the presence of AP2 and HIF1 sites. AP2 has been 
implicated in regulation of the BACE1 gene promoter [57]. HIF1 activity has been linked to 
neuroprotection against Aβ [58] but paradoxically upregulates BACE1 and results in greater 
generation of Aβ [59]. in addition, the presence of RBPJκ sites may be pathogenically 
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interesting, given that transcription factor's role in notch-associated inhibition of apoptosis 
[60]. NRSF is a potent repressor of transcription of neuron–specific genes in non–neuronal 
cells [61]. TBX5 is a developmental regulator that induces apoptosis [62]. THAP1 is a 
nuclear proapoptotic factor [63]. Factors such as NRSF, HIF1 or RBPJκ could function to 
downregulate Sp1 in healthy neuronal tissue, while factors such as THAP1 could be active 
during apoptotic or pathological states, such as in AD. These interactions would not be 
possible with the mouse Sp1 promoter, given that the sites are not available on the mouse 
sequence. Beyond the differences in predicted transcription factor binding sites, intronic 
regulation of hnRNA processing may also play a role in the differences observed between 
mouse and monkey Sp1 mRNA levels.
Upon examining Aβ peptide levels, we noted that in neither species did the peptide levels 
closely follow AβPP mRNA levels in the aging paradigm studied herein. We, therefore, 
examined differences in the 5′– and 3′–UTRs of mouse vs. cynomolgus monkey AβPP 
mRNA. We determined that the mouse sequence lacked two of three TOP motifs found in 
the human and monkey sequences. TOP presumably functions for translational repression 
[64]. The presence of multiple TOP sites in primate sequences vs. a single TOP site in 
mouse may indicate that, early in life, primate AβPP mRNA translation may be more 
strongly suppressed than mouse, and some mechanism later operates on the primate 5′–UTR 
to overcome this suppression. One such potential mechanism may involve the absence of a 
“CAGA” box within the 5′–UTR of mice and rats. This “CAGA” box is present in the AβPP 
5′–UTR sequences of plaque–forming mammalian species [18] and resides in a region of the 
AβPP 5′–UTR that has been shown to be targeted by the potential anti–AD drug phenserine 
[65, 66]. Activity of miRNA on the 5′–UTR in regulation of translation may also explain 
differences in mouse vs. monkey protein levels. It has been recently shown that miRNA can 
be active via the 5′–UTR in repression of mRNA translation [67].
Our examination of the 3′–UTR has also suggested avenues to explore for differential 
mRNA regulation. Two CPE sites were present in mouse mRNA vs. absent in primate. This 
motif stabilizes mRNA and increases posttranscriptional expression. However, it only does 
so up through the blastoderm stage [68]. AβPP and its Aβ product have developmental 
functions that have only been partially elucidated [69, 70]. It is possible that murid rodents 
have evolved a specific means of early–developmental regulation of AβPP translation via 
the 3′–UTR. However, in addition to CPE, we also determined that the human and monkey 
AβPP 3′–UTR sequences had three times as many GAIT motifs (an inhibitor of mRNA 
translation) as did mouse. This points toward aging–related derepression of translation to 
explain increasing levels of AβPP protein in primates. However, in addition to these 
differences, mouse AβPP 3′–UTR had one unique miRNA binding site, which may repress 
mouse AβPP translation, via 3′–UTR repression by miRNA binding [67]. Alternatively, the 
miRNA sites that occur in primate but not mouse sequences may function to activate 
primate AβPP mRNA translation, as has been determined to occur for tumor necrosis factor 
alpha [71]. Direct confirmation of the active status of these sites in the AβPP mRNAs would 
determine which mechanism or mechanisms are actually functioning for this particular gene.
With aging, other factors may additionally contribute to the amyloidogenic pathway. A 
recent study [72] with normal aging human beings found the non–amyloidogenic α–
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secretase pathway declined due to aging, and, while β–secretase activity was increased, 
levels of Aβ40 and Aβ42 did not change with age. Since they only measured the insoluble 
form of Aβ, this result did not represent the whole Aβ pool. Aging is also a crucial factor 
resulting in reduced Aβ clearance by degrading enzymes. Aging rats showed much less 
elimination of Aβ1–40 from brain to peripheral circulation than young rats [73].
In addition to aging–related factors, species–intrinsic differences also need to be considered, 
such as those we have recently demonstrated in our analysis of the human apolipoprotein E 
(APOE) gene promoter in human–origin vs. rodent–origin cell lines and nuclear extracts 
[74].
Regarding the aforementioned results and their interpretations, the overall mouse mRNA 
data is similar to that performed in an independent set of rats previously published [26]. An 
mRNA analysis of monkeys produced similar readings, as previously published by us for 
aged monkeys [75]. Confidence is also raised in the rodent protein data through 
measurement at multiple intermediate ages. The data points on the curves presented were 
derived from 3–4 animals. When considering these profiles, one may keep in mind that the 
overall signature profiles are more important than individual points on the curve. Similarity 
and contrast of the lifespan expression of amyloid pathway genes and their products between 
amyloid–producing species (cynomolgus monkey) and non–amyloid species (mouse) are the 
major focus of the present work.
Alternative explanations may suffice for the observed differences between mouse and 
monkey in AβPP expression and Aβ metabolism. While both populations were maintained in 
laboratory conditions, these conditions could not, of course, have been identical. Each 
species has different nutritional requirements, requiring that their feed differ from each 
other. This introduces the potential for dietary effects on AβPP expression, similar to those 
seen for the PSEN1 gene [76]. Epigenetic effects also cannot be ruled out [77]. Likewise, 
the great divergence in overall lifespan raises the possibility of a fundamental difference of 
aging programs that is not limited to SP1, AβPP, or BACE1. That is to say, differences seen 
in the expression and activity of these genes' products may actually reflect a deeper and 
more profound difference between the two species, altogether, one that raises the question of 
applicability of results from one model to another.
In a broader context, the present work underscores the importance of studying the regulation 
of gene expression in relation to the disease process. Structural similarity of gene coding 
sequences is often taken as a strong indicator of the suitability of a model system, especially 
when a model is transgenic, since it has the exact human coding sequence. Experience has 
shown that such models have limits. Notably, a natural model considered as close as 99% 
homologous to humans, such as the chimpanzee, does not afford a 99% level of gene–based 
pathogenic functional similarity. Fundamental differences in gene regulation and interaction 
may play a more important role in determining differences than primary DNA sequence 
[78]. These regulatory differences could likewise be significantly influenced by 
environmental factors, such as diet and metals, at the very early stage of development and, 
importantly, could be manifested later in the life after prolong latency as explained in a 
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recently proposed ‘LEARn’ model (Latent Early–life Associated Regulation) [74] and 
discussed for the somatic epitype [79].
In summary, we have examined the lifetime profiles of intermediates in the amyloid cascade 
pathway in both non plaque–forming rodents and plaque–forming primates (Table 5). We 
found that the expression pattern of AβPP mRNA mirrors that of the transcription factor 
Sp1, and thus SP1 may be a lifelong regulator of the AβPP gene. We also noted that in both 
species, there is a complex relationship between AβPP mRNA expression and AβPP protein 
levels. Furthermore, in non plaque–forming rodents, Aβ does not accumulate in the brain 
with aging; however, in plaque–forming primates, both AβPP protein and Aβ accumulated. 
These findings are summarized diagrammatically in Fig. 9. Proteolytic enzyme activity does 
not match the production levels of Aβ. The discrepancy between AβPP mRNA and AβPP 
protein as well as Aβ in both species may be due to different nucleic acid structure–based 
mechanisms, as our comparisons of genomic and mRNA sequences suggest. In mice, 
posttranslational pathways related to Aβ clearance or degradation appears to prevent any 
accumulation Aβ levels. On the other hand, enhanced translational efficiency or decreased 
AβPP degradation may lead to an accumulation of AβPP and Aβ in non–human primates. 
Posttranslational regulation and AβPP protein metabolism may also play a crucial role in 
amyloidogenesis.
Our results point toward the need to carefully and rationally select animal models, even 
transgenic models, to understand fundamental molecular mechanisms of human disease. 
Differential regulation of “pathogenic” genes points toward the need for models that 
preserve a similar regulatory milieu to the ultimate target species (in the case of AD, 
human). Transgenic models may be able to fulfill this need, but each level of regulation 
(transcriptional, translational, posttranslational) requires more transgenes be combined, and 
raises the possibility that the transgenes, themselves, may be subject to potentially important 
species–differentiated regulation.
The current prospect for mouse models of AD is mixed, with much work done on animals 
transgenic for mutant AβPP, mutant PSEN1, and the two combined. Likewise, there are also 
knockouts for AβPP, BACE1, MAPT, and other genes implicated in AD. Most of the 
transgenic lines use a “strong” promoter specifically to ensure high production of the protein 
of interest. This practice has also meant that studying possible contributions of gene 
regulation to etiology may have been sidestepped, entirely. Recently, mouse lines have 
begun to be developed that are transgenic for both the coding sequence and promoter of 
AD–related genes of interest, such as tau. It should be noted that work with the promoters of 
the AD–associated gene APOE for mouse and human have revealed that the human 
promoter can have different responses in rodent–origin cell lines and nuclear extracts than in 
cells and extracts of human origin [74]. Thus, even though improvements are likely in 
rodent models, there may always be an inherent limitation to the practice. The authors do not 
wish this cautionary statement regarding mouse models to be taken as an indictment of 
animal modeling of AD, altogether. This work raises the question of the applicability of a 
particular model species toward translation of AD research to humans. Even though there 
are stark contrasts between mouse and primate expression patterns, other rodent species, 
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such as guinea pig [80], could serve as useful non–transgenic models for APP processing 
and expression.
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Fig. 1. Lifetime mRNA expression changes in AD related genes (Sp1, AβPP) in the mouse brain 
cortex
Relative quantification was measured by using 7500 Real–Time PCR System (Applied 
Biosystems, CA) with β–actin serving as the endogenous control. A) Relative Sp1 mRNA 
signal. B) Relative AβPP mRNA signal. Each data point in the curve is the mean + SEM 
(n=3-4 animals). “*” denotes significant difference for SP1 or AβPP mRNA time point when 
compared to that of PND 365.
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Fig. 2. Lifetime profile of AD related proteins (AβPP, SP1 Aβ) in the mouse brain
Protein from cortical tissue of wild–type mice was isolated, equal protein amounts were 
loaded and probed with 22C11 AβPP N–terminus antibody with SDS–PAGE western blot 
analysis as described in the methods section. The SP1 antibody used is mentioned in the 
methods section. Protein was also used to measure Aβ 1–40 by a sandwich ELISA assay 
(IBL, Japan). Six time points are shown. Representative blots are shown in insets for 
western analysis. A) Relative AβPP levels; B) Relative SP1 levels; C) Aβ40 levels. Each 
data point in the curve is the mean + SEM (n=3 animals). “*” denotes significant difference 
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between Aβ levels at PND 630 as compared to PND 365. Western blot results were 
normalized to β–actin signal.
Dosunmu et al. Page 22
J Alzheimers Dis. Author manuscript; available in PMC 2016 February 22.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Fig. 3. Lifespan mRNA expression changes in AD related genes (Sp1, AβPP, BACE1) in the 
primate brain cortex
Relative quantification was measured by using 7500 Real–Time PCR System (Applied 
Biosystems, CA) with GAPDH serving as the endogenous control. Three time points are 
shown. Representative blots are shown in insets for western analysis. A) Relative AβPP 
mRNA. B) Relative SP1 mRNA. C) Relative BACE1 mRNA. Each data point in the curve 
is the mean + SEM (n=3 monkeys). “*” denotes significant difference for SP1 or AβPP 
mRNA time point when compared to 12 years age.
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Fig. 4. Lifespan profile of AD related proteins (AβPP, SP1, and Aβ) in the primate brain
Protein from cortical tissue of Cynomolgus primate was isolated and probed with 22C11 
AβPP N–terminus antibody with SDS–PAGE western blot analysis as described in the text. 
The SP1 antibody used is mentioned in the methods section. Protein was also used to 
measure Beta amyloid (Aβ) 1–40 using an ELISA assay (IBL, Japan). A) Relative AβPP 
protein signal; B) Relative SP1 signal; C. Aβ40 levels. Each data point in the curve is the 
mean + SEM (n=3 monkeys). Western blot results were normalized to β–actin signal.
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Fig. 5. Lifespan profile of BACE1 secretase activity in the mouse and primate brain
Protein from cortical tissue of mouse and Cynomolgus primate was isolated and BACE1 
activity measured using the BACE1 activity assay kit (R&D Systems, Inc., MN). The y–axis 
reports raw intensity numbers from fluorescence spectrophotometry. A) BACE1 activity in 
mice at six time points. B) BACE1 activity in monkeys at three time points. Each data point 
in the curve is the mean + SEM (n=3 animals). “*” denotes significant difference for SP1 or 
AβPP mRNA time point when compared to PND 365 for mouse or 12 years age for monkey.
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Fig. 6. Genomic homology of mouse Sp1 and AβPP with human Sp1 and AβPP
Genomic reference sequences for human Sp1 and AβPP were used to BLAST the mouse 
reference genomic assembly as described in the text. Diagram represents coverage of 
homological regions over entire genomic sequences. Colors indicate percent homology as 
indicated by keys on figure. A) Homology of mouse Sp1 vs. human Sp1. Numbers along 
alignment indicate position in human chromosomal genomic sequence. B) Homology of 
mouse AβPP vs. human AβPP. Numbers along alignment indicate position in human 
reference gene sequence [81]. C) Homology of monkey Sp1 vs. human Sp1. Numbers along 
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alignment indicate position in human chromosomal genomic sequence. D) Homology of 
monkey AβPP vs. human AβPP. Numbers along alignment indicate position in human 
reference gene sequence [81].
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Fig. 7. Homology of mouse and monkey Sp1 promoter sequences with human Sp1 sequence
Sequences of 4kb length upstream of the +1 TSS were taken from genomic reference 
sequences for mouse, rhesus monkey, and human Sp1, and ClustalX was used to align each 
of the monkey and mouse sequences to the human. Diagram represents percent homology of 
each non–human sequence with human sequence in a 50–bp window. A) Homology of 
mouse Sp1 promoter vs. human Sp1 promoter. B) Homology of monkey Sp1 promoter vs. 
human SP1 promoter.
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Fig. 8. Relationship between mRNA and protein product levels of selected AD–related genes in 
mouse vs. monkey
Diagram illustrates levels of mRNA vs. protein product levels of SP1 and APP in animal 
models studied. Solid line indicates mRNA levels over lifespan while dashed line indicates 
protein levels over lifespan. For each species, mRNA and protein levels diverge from each 
other in later life, albeit in opposite directions when comparing species to species. A) Mouse 
mRNA and protein levels. B) Monkey mRNA and protein levels.
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Table 2
Unique transcription factor family sites in Sp1 promoters of human and monkey vs. mouse.
Factor Family Human Monkey Mouse
AARE AARE binding factors −3830, −2743, −1833 −3050, −2132
AP2 Activator protein 2 −1232, −1232
AIRE Autoimmune regulatory element binding factor −3472, −3308, 
−2044, −1476
BARBIE Barbiturate-inducible element box from pro+eukaryotic genes −2272, −1707, 
−732, −671
TBX5 Brachyury gene, mesoderm developmental factor −3920, −823 −806
KAISO BTB/POZ (broad complex, TramTrack, Bric à brac/pox viruses and 
zinc fingers) transcription factor
−1970 −2270
DICE Downstream Immunoglobulin Control Element, critical for B cell 
activity and specificity
−1636
GTF3R4 GTF2I repeat domain–containing factors −58
NUDR Homolog to deformed epidermal autoregulatory factor–1 from D. 
melanogaster
−872, −766
FLI Human and murine ETS1 factors −313 −294
HIF1 Hypoxia inducible factor, bHLH/PAS protein family −1877, −330 −3910
HIC1 Krueppel–like C2H2 zinc finger factors hypermethylated in cancer −482 −463
TCF11 MAF and AP1 related factors −364 −345
MEF3 MEF3 binding sites −2731 −3834, −3204
NRSE Neuron-restrictive silencer factor −2820, 48 67
PTF1 Pancreas transcription factor 1, heterotrimeric transcription factor −1281 −1258
RBPJκ Notch–associated RBPJ–κ −3977 −3646, −3635
THAP1 THAP domain containing protein −2799 −3106
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Table 3
Presence of selected motifs in AβPP 5′–UTR mRNA from human, monkey, and mouse.
Motif Human Monkey Mouse
TSSa 1 1 1
AUG 148 144 146
TOPb 6, 52, 131 5, 51, 127 5
hsac–miR–324–3p 54 44
hsa–miR–328 29
hsa–miR–346 69 62
hsa–miR–502 71 70
hsa–miR–504 123 119
mmud–miR–296 33 35 35
mmu–miR–324–3p 54 44
mmu–miR–328 29
mmu–miR–346 63 62
Sites unique to mouse are in boldface. Sites found in monkey and human but not mouse are italic.
a
+1 Transcription Start Site
b
Terminal Oligopyrimidine Tract
c
Homo sapiens, human
d
Mus musculus, mouse
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Table 4
Presence of selected motifs in AβPP 3′–UTR mRNA from human, monkey, and mouse.
Motif Human Monkey Mouse
stop codon 2458a 2229a 2231b
AβPP SCEc 2659 2435 2445
CPEd 2931, 2941
GAITe 2704, 2787, 3013, 3096, 3130, 3392, 3397 2291, 2562, 2788, 2901, 2938 2580, 2638
SECISf 3478, 3479 2361, 2362, 2365 2567
hsa–miR–17–5p 3155 2926
hsa–miR–20b 3156 2927
hsa–miR–99b 2960
hsa–miR–106b 3158 2929
hsa–miR–483 3181 2952
hsa–miR–485–5p 2464 2235
mmu–miR–17–5p 3155 2926
mmu–miR–20a 3156 2927
mmu–miR–99b 2960
mmu–miR–106a 3157 2928
mmu–miR–106b 3158 2929
mmu–miR–485–5p 2464 2235
Sites unique to mouse are in boldface. Sites found in monkey and human but not mouse are italic.
a
“UAG”
b
“UAA”
cAmyloid–β Precursor Protein mRNA Stability Control Element
dCytoplasmic Polyadenylation Element
eGamma Interferon Activated Inhibitor of Ceruloplasmin mRNA Translation
fSelenocysteine Insertion Sequence–type 1
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Table 5
Summary of mRNA expression, protein or peptide levels, and enzymatic activity, monkey vs. mouse.
Monkey Mouse
Gene mRNA Protein/Peptide/Activity mRNA Protein/Peptide/Activity
SP1 ↓ ↑ ↑ ↑
AβPP ↓ ↑ ↑ ↑
BACE1 ↓ ↓ nca ↑
Aβ ↑ ↓
aNo change
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